OsimertinibTreatment failure secondary to drug resistance due to EGFR triple mutation: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2018年 / 1721卷 / 1期

关键词：

D O I：

10.1007/s40278-018-52264-9

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：227 / 227

相关论文

共 50 条

[1] ErlotinibAcquired drug resistance following EGFR mutation: case report
Reactions Weekly, 2017, 1658 (1) : 184 - 184
[2] Foscarnet/ganciclovirEmergent drug resistance secondary to gene mutation: case report
Reactions Weekly, 2019, 1740 (1) : 160 - 160
[3] Imatinib/nilotinibDevelopment of drug resistance due to gene mutation: case report
Reactions Weekly, 2022, 1925 (1) : 270 - 270
[4] AfatinibResistance due to EGFR-T790M resistance mutation: case report
Reactions Weekly, 2018, 1715 (1) : 22 - 22
[5] Posaconazole/voriconazoleTreatment failure secondary to development of drug resistance: case report
Reactions Weekly, 2019, 1752 (1) : 331 - 331
[6] Erlotinib/gefitinibTreatment failure secondary to acquired drug resistance: case report
Reactions Weekly, 2018, 1716 (1) : 131 - 131
[7] AntineoplasticsDevelopment of drug resistance following secondary BRCA 2 mutation: case report
Reactions Weekly, 2020, 1804 (1) : 42 - 42
[8] AntineoplasticsTreatment failure secondary to drug resistance along with various toxicities: case report
Reactions Weekly, 2018, 1713 (1) : 37 - 37
[9] AntiretroviralsLiver adverse reaction and virological failure secondary to drug resistance: case report
Reactions Weekly, 2021, 1860 (1) : 64 - 64
[10] AfatinibAcquired resistance due to gene mutation: case report
Reactions Weekly, 2022, 1906 (1) : 25 - 25

← 1 2 3 4 5 →